Cytokinetics oral heart failure agent begins Phase I
This article was originally published in Pharmaceutical Approvals Monthly
After releasing top-line results of its Phase I intravenous CK-1827452 candidate to treat acute and chronic heart failure, Cytokinetics announced it will begin Phase I trials of an oral formulation of the compound. The company hopes to study the intravenous formulation in acutely decompensated heart failure patients in a hospital setting and transition them to an oral dose in an outpatient setting. Cytokinetics is already considering a sales force of 100-200 full-time employees for the drug (1Pharmaceutical Approvals Monthly August 2006, p. 6)...
You may also be interested in...
Cytokinetics is casting a wider net with its development program for ispinesib following the targeted oncologic’s failure earlier this year in a Phase II lung cancer trial.
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.